InspireMD
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4 Menorat Hamaor St, Tel Aviv, Tel Aviv,...Phone Number
+972 36917691Website
www.inspiremd.comRevenue
$10.8 MillionStock Symbol
NSPRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About InspireMD
InspireMD, Inc., is a medical device company that is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB. The company is based in Tel Aviv, Israel.Explore more
InspireMD Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InspireMD your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when InspireMD launches new products
Check if InspireMD has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if InspireMD is spiking on competitors!
Click to see if InspireMD had a recent Job posting/layoffs
Funding: Get notified immidiatlly once InspireMD has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
InspireMD, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at InspireMD
Earning: See what the market has to say on InspireMD recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
InspireMD is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
InspireMD is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about InspireMD.
InspireMD financials insights
Gather financial insights about InspireMD, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$11M
2025
Private Equity
$40.1M
Stock/Share Issuance
$58M
InspireMD Tech Stack
A closer look at the technologies used by InspireMD
Most Recent Scoops
Hiring Plans
InspireMD has more open roles in Operations than it has had at any time in the past 6 months.
Hiring Plans
Earnings
reported total revenue of $3.1 million for Q4 2025, an increase of 62% compared to revenue of $1.9 million for Q4 2024. This growth was driven by the launch of CGuard Prime in the US and increased penetration of international markets with CGuard.
Earnings, Product Launch, Finance
Earnings
reported international revenue of $2.3 million for Q4 2025, reflecting growth of 17% compared to $1.9 million for Q4 2024. The majority of the international growth was driven by higher unit sales, while changes in foreign exchange rates contributed growth of about 7% to international results.
Earnings, Finance
Earnings
reported total operating expenses of $13.3 million for Q4 2025, an increase of $3.4 million compared to $9.8 million for Q4 2024. This increase was primarily due to higher commercial staffing levels and marketing activities for the US commercial launch of CGuard Prime.
Earnings, Spending/Investment, Finance
Earnings
Earnings, Finance
InspireMD News & Media
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting proceduresInspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck atInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13th at 4:20 pm Pacific Time (PT).InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call May 4, 2026 4:30 PM EDTCompany ParticipantsMarvin Slosman - President, CEO & DirectorMichael Lawless - CFO,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding InspireMD
Sign Up For FreeTo access detailed company insights
InspireMD, Inc., is a medical device company that is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outst... Read More
